Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1398-9995.2009.02114.x | DOI Listing |
Clin Exp Dermatol
January 2025
Boston Specialists, Boston, MA, USA.
Indian Dermatol Online J
August 2024
Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India.
J Cutan Pathol
November 2024
Dermatology Department, Virgen del Rocío University Hospital, Seville, Spain.
Clin Cosmet Investig Dermatol
May 2024
Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Background: Cytophagic histiocytic panniculitis (CHP) is a rare panniculitis associated with systemic features characterized by the infiltration of subcutaneous adipose tissue by benign-appearing T lymphocytes and phagocytic histiocytes, mimicking hemophagocytic lymphohistiocytosis (HLH) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
Purpose: To establish the clinicopathological features and response to treatment of CHP and evaluate the prognosis of patients and guide therapy based on the current state of knowledge.
Material And Methods: Clinical, laboratory, histopathological, and outcome data of 12 patients with CHP were retrospectively collected between 2009 and 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!